**b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

*Mycobacterium tuberculosis* Gateway<sup>®</sup> Clone Set, Recombinant in *Escherichia coli*, Plates 1-42

# Catalog No. NR-19274

## For research use only. Not for human use.

### **Contributor:**

Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute

### Manufacturer:

**BEI Resources** 

#### **Product Description:**

NR-19274 consists of Plates 1-42 (BEI Resources NR-19637 through NR-19678) of the *Mycobacterium tuberculosis (M. tuberculosis)* Gateway<sup>®</sup> clone set. Detailed information is available on the Product Information Sheet and Certificate of Analysis for each individual plate.

The *M. tuberculosis* Gateway<sup>®</sup> clone set (Plates 1-42) contains 3724 sequence validated clones (3294 *M. tuberculosis*, strain H37Rv clones supplemented with 430 unique open reading frames (ORF) from *M. tuberculosis*, strain CDC1551) cloned in *Escherichia coli* (*E. coli*) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR 221 with an ATG start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.

Information related to the use of Gateway<sup>®</sup> Clones can be obtained from Invitrogen<sup>TM</sup>. Recombination was facilitated through an *att*B substrate (*att*B-PCR product or a linearized *att*B expression clone) with an *att*P substrate (pDONR<sup>TM</sup>221) to create an *att*L-containing entry clone. The entry clone contains recombinational cloning sites, *att*L1 and *att*L2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen<sup>TM</sup> Gateway<sup>®</sup> Technology Manual for additional details.

## Material Provided:

Every inoculated well of each 96-well plate contains approximately 40  $\mu$ L of *E. coli* culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50  $\mu$ g/mL kanamycin supplemented with 15% glycerol.

<u>Note:</u> Production in the 96-well format has a potential for cross-contamination. Individual mutants should be checked by the recipient prior to use.

## Packaging/Storage:

NR-19274 was packaged aseptically in 96-well plates. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

## **Growth Conditions:**

# Media:

LB Broth or Agar containing 50 µg/mL kanamycin

Incubation:

Temperature: *E. coli*, strain DH10B clones should be grown at 37°C.

Atmosphere: Aerobic

Propagation:

- 1. Scrape top of frozen well with a pipette tip and streak onto agar plate.
- 2. Incubate the plates at 37°C for 18 to 24 hours.

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Mycobacterium tuberculosis* Gateway<sup>®</sup> Clone Set, Recombinant in *Escherichia coli*, Plates 1-42, NR-19274."

### **Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5/bcc.htm.

## **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal.  $ATCC^{\textcircled{B}}$  and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S.

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Government, ATCC<sup>®</sup>, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### **Use Restrictions:**

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

### **References:**

- Cole, S. T., et al. "Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence." <u>Nature</u> 393 (1998): 537-544. PubMed: 9634230.
- Camus, J. C., et al. "Re-Annotation of the Genome Sequence of *Mycobacterium tuberculosis* H37Rv." <u>Microbiology</u> 148 (2002): 2967-2973. PubMed: 12368430.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.

